source
- Argenx shares tumble 15% after Phase 3 Sjögren’s study of Vyvgart halted for futilityArgenx reported that an independent monitoring board recommended stopping its Phase 3 trial of Vyvgart in Sjögren’s disease due to futility, based on an interim analysis. The decision came earlier…
- Viatris to acquire Pacira BioSciences for $1.65 billion, adding two non-opioid pain drugsViatris announced Thursday it will purchase Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share, a 45% premium to the prior close. The acquisition gives Viatris control of Pacira…